Werewolf Therapeutics develops conditionally activated therapeutics engineered to stimulate the immune system for cancer and other immune-mediated conditions. News about HOWL centers on the company’s PREDATOR platform, INDUKINE molecules, INDUCER T cell engager work, and programs such as WTX-124 and WTX-330.
Recurring updates include clinical and preclinical data presentations, FDA regulatory designations, operating and financial results, program licensing or asset-rights activity, capital-structure actions, shareholder voting matters, and corporate-strategy updates tied to the company’s oncology-focused development pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Werewolf Therapeutics (Nasdaq: HOWL) announced the publication of preclinical data for mWTX-330, an Interleukin-12 INDUKINE molecule, in Cancer Immunology Research. This study demonstrates that mWTX-330 effectively stimulates an anti-tumor immune response by selectively delivering IL-12 to the tumor microenvironment while minimizing systemic toxicity. Key findings include robust immune activation in multiple tumor models and improved T-cell activity without signs of exhaustion. The company is preparing for a Phase 1 clinical trial for WTX-330 in patients with advanced solid tumors or lymphoma resistant to checkpoint inhibitors. The trial aims to evaluate safety and efficacy, marking a significant step in Werewolf's mission to enhance cancer treatments through targeted immune activation.